Pioneering technology to address threatened miscarriage secures £1 million funding and moves towards clinical trials

• Scientists developing a pioneering device designed to address threatened miscarriage have secured £1 million in NIHR funding to begin clinical trials

• Designed to deliver vital doses of progesterone, the Callavid® device stands to help over 150,000 women each year in the UK

• If approved, it would become the world’s first drug-device combination product to treat threatened miscarriage

See full press release here.